Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	DNA Virus Infections, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Infections, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, anogenital human papillomavirus infection, cervix disorder, common wart, dysplasia of cervix, female reproductive system disorder, female reproductive system neoplasm, human papilloma virus infection, infectious disease, neoplasm, precancerous condition, sexually transmitted disease, skin disorder, skin disorder caused by infection, uterine disorder, viral infectious disease, viral sexually transmitted disease	Active, not recruiting	Phase 3	2025-11-21		NCT04537156

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	3
Xiamen Innovax Biotech Co., Ltd	8
Xiamen University	16

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Jiangsu Provincial Centre for Disease Control and Prevention	Nanjing	China	2
Sichuan Provincial Centre for Disease Control and Prevention	Chengdu	China	2